Physician profile
Abir Abdo
NPI 1205071164
$765.48
in general payments reported to CMS, 2019-2025
13 companies · $165 in 2025
The $165 reported for 2025 was more than what a typical Geriatric Medicine (Internal Medicine) provider received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $231 · 2023: $178 · 2024: $191 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $534.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $534.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $326.49 | 2022-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abiomed | $114.78 | 2023 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $59.52 | 2024-2025 | |
| Abbvie INC. | $51.26 | 2024-2025 | |
| Lilly USA, LLC | $48.77 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $38.83 | 2023-2024 | Wegovy |
| Glaxosmithkline, LLC. | $35.40 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Acadia Pharmaceuticals INC | $31.74 | 2025 | Nuplazid |
| Exact Sciences Corporation | $16.64 | 2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $14.29 | 2023 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.59 | 2025 | Jardiance |
| Boston Scientific Corporation | $13.53 | 2023 | Watchman Flx |
| Sumitomo Pharma America, INC. | $0.64 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abir Abdo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.